PAX7 and sarcopenia: To optimize the TNF‐α treatment conditions for sarcopenia modelling, we first exposed hSkMOs to varying concentrations of TNF‐α (0, 5, 10, and 20 ng/mL) for 2 days and analysed the number of PAX7+ SCs by immunohistochemistry.